Immunogenicity paradox following biosimilar switching: Mechanistic insights needed - 10/06/26
Doi : 10.1016/j.jaad.2026.01.097
Bobiao Ning, PhD a, Baohua Li, MD b, Mengyao Jiang, PhD a, Ping Song, PhD c, ⁎ 
a Guang'anmen Hospital, China Academy of Traditional Chinese Medicine, Beijing, China
b China Academy of Chinese Medical Sciences Eye Hospital, Beijing, China
c Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
∗ Correspondence to: Ping Song, PhD, Xiyuan Hospital, China Academy of Chinese Medical Sciences, No 1, Xiyuan Playground, Haidian Dt, Beijing 100091, China Xiyuan Hospital China Academy of Chinese Medical Sciences No 1 Xiyuan Playground Haidian Dt Beijing 100091 China
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Wednesday 10 June 2026
Key words : biologics, biosimilar, psoriasis, randomized clinical trial
Le texte complet de cet article est disponible en PDF.
| Drs Ning and Li contributed equally. |
|
| Funding sources: This research was funded by the National Natural Science Foundation of China ( 82474521 ). |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
|
| This article represents an uncorrected author proof. |
© 2026
Publié par Elsevier Masson SAS.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?